NCT06420089 - CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 4, 2024

Primary Completion Date

August 30, 2026

Study Completion Date

June 30, 2027

Conditions

T Cell Non-Hodgkin Lymphoma

Interventions

DRUG

Senza5 CART5

The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells

Trial Locations (2)

RECRUITING

Columbia University Irving Medical Center, New York

RECRUITING

University of Pennsylvania - Abramson Caner Center, Philadelphia